Center for Computational Medicine in Cardiology, Institute of Computational Science, Università della Svizzera italiana, Lugano, Switzerland.
Carmen Team, Inria Bordeaux-Sud-Ouest, Talence, France.
Europace. 2021 Mar 4;23(23 Suppl 1):i161-i168. doi: 10.1093/europace/euaa413.
Recent clinical studies showed that antiarrhythmic drug (AAD) treatment and pulmonary vein isolation (PVI) synergistically reduce atrial fibrillation (AF) recurrences after initially successful ablation. Among newly developed atrial-selective AADs, inhibitors of the G-protein-gated acetylcholine-activated inward rectifier current (IKACh) were shown to effectively suppress AF in an experimental model but have not yet been evaluated clinically. We tested in silico whether inhibition of inward rectifier current or its combination with PVI reduces AF inducibility.
We simulated the effect of inward rectifier current blockade (IK blockade), PVI, and their combination on AF inducibility in a detailed three-dimensional model of the human atria with different degrees of fibrosis. IK blockade was simulated with a 30% reduction of its conductivity. Atrial fibrillation was initiated using incremental pacing applied at 20 different locations, in both atria. IK blockade effectively prevented AF induction in simulations without fibrosis as did PVI in simulations without fibrosis and with moderate fibrosis. Both interventions lost their efficacy in severe fibrosis. The combination of IK blockade and PVI prevented AF in simulations without fibrosis, with moderate fibrosis, and even with severe fibrosis. The combined therapy strongly decreased the number of fibrillation waves, due to a synergistic reduction of wavefront generation rate while the wavefront lifespan remained unchanged.
Newly developed blockers of atrial-specific inward rectifier currents, such as IKAch, might prevent AF occurrences and when combined with PVI effectively supress AF recurrences in human.
最近的临床研究表明,抗心律失常药物(AAD)治疗与肺静脉隔离(PVI)协同作用,可降低最初成功消融后心房颤动(AF)的复发率。在新开发的心房选择性 AAD 中,G 蛋白门控乙酰胆碱激活内向整流电流(IKACh)抑制剂已被证明可在实验模型中有效抑制 AF,但尚未在临床上进行评估。我们通过计算机模拟测试了内向整流电流抑制或其与 PVI 的联合使用是否可以降低 AF 的可诱导性。
我们在具有不同纤维化程度的人类心房的详细三维模型中模拟了内向整流电流阻断(IK 阻断)、PVI 及其组合对 AF 可诱导性的影响。IK 阻断的模拟方法是将其电导率降低 30%。在两个心房中,使用递增起搏在 20 个不同位置起始 AF。在没有纤维化的模拟中,IK 阻断可有效防止 AF 诱导,而在没有纤维化和中度纤维化的模拟中,PVI 也可有效防止 AF 诱导。在严重纤维化的模拟中,这两种干预措施均失去了疗效。在没有纤维化、中度纤维化甚至严重纤维化的模拟中,IK 阻断和 PVI 的联合治疗可防止 AF。联合治疗可通过协同降低波前生成率来防止 AF 的发生,同时保持波前寿命不变,从而强烈减少了纤维颤动波的数量。
新型心房特异性内向整流电流阻断剂,如 IKAch,可能会预防 AF 的发生,并且与 PVI 联合使用时可有效抑制人类的 AF 复发。